Amit Taneja

Amit Taneja

Intensive Care Medicine | Pulmonary Medicine
8900 W. Doyne Ave.
Milwaukee, WI 53226

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications

Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.

Model-Based Meta-Analysis With MonolixSuite: A Tutorial for Longitudinal Categorical and Continuous Data.

Journal: CPT: pharmacometrics & systems pharmacology
Published: July 08, 2025

Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.

Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.

Journal: Drugs in R&D
Published: October 22, 2024

Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.

Prediction of Disease Progression and Clinical Response in Systemic Sclerosis: Experience From a Proof-of-Concept Trial.

Journal: ACR open rheumatology
Published: December 01, 2023

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.

Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.

Journal: JAMA
Published: May 09, 2023

Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.

Drug-drug interaction prediction of ziritaxestat using a physiologically based enzyme and transporter pharmacokinetic network interaction model.

Journal: Clinical and translational science
Published: April 18, 2023

ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis.

ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis.

Journal: Clinical pharmacology and therapeutics
Published: April 05, 2023

The authors reply.

The authors reply.

Journal: Critical care medicine
Published: April 18, 2020

Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb®) in the management of septic shock: A retrospective observational study.

Hemoadsorption by extracorporeal cytokine adsorption therapy (CytoSorb®) in the management of septic shock: A retrospective observational study.

Journal: The International journal of artificial organs
Published: December 24, 2019

Frequency, Risk Factors, Causes, and Consequences of Diagnostic Errors in Critically Ill Medical Patients: A Retrospective Cohort Study.

Frequency, Risk Factors, Causes, and Consequences of Diagnostic Errors in Critically Ill Medical Patients: A Retrospective Cohort Study.

Journal: Critical care medicine
Published: September 17, 2019

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.

Journal: Clinical pharmacokinetics
Published: April 07, 2019

Computed Tomography Bronchus Sign and the Diagnostic Yield of Guided Bronchoscopy for Peripheral Pulmonary Lesions. A Systematic Review and Meta-Analysis.

Computed Tomography Bronchus Sign and the Diagnostic Yield of Guided Bronchoscopy for Peripheral Pulmonary Lesions. A Systematic Review and Meta-Analysis.

Journal: Annals of the American Thoracic Society
Published: June 08, 2018

Timely Transthoracic Echocardiogram in Pulmonary Embolism-Is It Worth the Trouble?

Timely Transthoracic Echocardiogram in Pulmonary Embolism-Is It Worth the Trouble?

Journal: Critical care medicine
Published: May 16, 2018
Showing 1-12 of 34

Last Updated: 09/26/2026